Trinity Biotech Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	5.14	5.17	3.69	6.58	25.91
Cash & Short-Term Investments	5.14	5.17	3.69	6.58	25.91
Cash Growth	-0.56%	39.99%	-43.89%	-74.61%	-5.18%
Accounts Receivable	9.69	13.88	11.34	13.45	14.17
Other Receivables	0.59	0.73	1.67	2.21	1.54
Receivables	10.28	14.6	13.01	15.66	15.71
Inventory	18.83	19.37	19.93	22.5	29.12
Prepaid Expenses	1.65	1.98	2.04	1.93	1.95
Other Current Assets	-	-	0.37	-	-
Total Current Assets	35.9	41.12	39.04	46.67	72.69
Property, Plant & Equipment	5.3	4.62	1.89	5.68	5.92
Long-Term Investments	2.77	2.46	-	-	-
Goodwill	13.97	13.84	-	12.54	12.54
Other Intangible Assets	19.45	16.55	1.17	5.72	5.77
Long-Term Accounts Receivable	-	-	0.04	0.08	0.15
Long-Term Deferred Tax Assets	3.92	3.55	1.98	4.22	4.1
Long-Term Deferred Charges	23.57	20.95	15.1	17.01	17.68
Other Long-Term Assets	0.28	0.19	0.22	0.18	0.06
Total Assets	105.17	103.29	59.44	92.1	118.9

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	11.48	6.83	3.89	6.21	6.76
Accrued Expenses	17.63	14.37	8.07	9.06	8.12
Current Portion of Long-Term Debt	108.23	0.21	0.21	0.21	83.31
Current Portion of Leases	2.59	2.29	1.69	1.68	1.98
Current Income Taxes Payable	0.35	0.36	0.28	0.03	0.02
Current Unearned Revenue	0.19	0.2	0.05	0.11	0.21
Other Current Liabilities	0.76	7.84	0.85	0.05	0.08
Total Current Liabilities	141.21	32.1	15.04	17.34	100.49
Long-Term Debt	16.33	87.79	54.65	58.05	-
Long-Term Leases	10.84	10.48	10.87	12.27	13.87
Long-Term Deferred Tax Liabilities	4.67	4.56	2.3	5.06	4.86
Other Long-Term Liabilities	4.1	3.55	0.53	1.57	-
Total Liabilities	177.15	138.47	83.38	94.28	119.21

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	0.04	4.19	1.97	1.96	1.21
Additional Paid-In Capital	63.8	63.4	46.62	46.46	16.19
Retained Earnings	-116.17	-79.12	-48.64	-26.7	12.56
Treasury Stock	-24.92	-24.92	-24.92	-24.92	-24.92
Comprehensive Income & Other	5.27	1.27	1.03	1.02	-5.36
Shareholders' Equity	-71.98	-35.18	-23.95	-2.18	-0.32
Total Liabilities & Equity	105.17	103.29	59.44	92.1	118.9

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	137.98	100.76	67.43	72.2	99.16
Net Cash (Debt)	-132.85	-95.6	-63.74	-65.62	-73.25
Net Cash Growth	-	-	-	-	-
Net Cash Per Share	-214.55	-159.69	-249.78	-291.78	-525.65
Filing Date Shares Outstanding	0.68	0.62	0.32	0.25	0.18
Total Common Shares Outstanding	0.62	0.6	0.26	0.25	0.14
Working Capital	-105.31	9.03	24.01	29.33	-27.8
Book Value Per Share	-115.42	-58.77	-93.73	-8.57	-2.29
Tangible Book Value	-105.4	-65.57	-25.12	-20.44	-18.62
Tangible Book Value Per Share	-169.00	-109.53	-98.29	-80.44	-133.63
Land	28.56	26.78	24.27	24.68	24.33
Machinery	41.44	41.03	39.04	38.22	36.54
Leasehold Improvements	2.83	2.81	2.76	2.7	2.59

SEC Filings: 10-K · 10-Q